Evidence map›Paper›PMID 42677352›Full record

ArticleClinical pharmacology in drug development2026

An Open-Label Study Investigating the 5-HT

Ethan S Burstein, Christine Sandiego, Brian Raether, Xiaoshu Feng, Bryan Dirks, Mona Darwish, Peter Zhang, David S Russell, Eugenii A Rabiner, Sanjeev Pathak

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology in drug development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ethan S BursteinAcadia Pharmaceuticals Inc., San Diego, CA, USA.
Christine SandiegoPerceptive Discovery, New Haven, CT, USA.
Brian RaetherAcadia Pharmaceuticals Inc., San Diego, CA, USA.
Xiaoshu FengAcadia Pharmaceuticals Inc., Princeton, NJ, USA.
Bryan DirksAcadia Pharmaceuticals Inc., Princeton, NJ, USA.
Mona DarwishAcadia Pharmaceuticals Inc., Princeton, NJ, USA.
Peter ZhangAcadia Pharmaceuticals Inc., San Diego, CA, USA.
David S RussellPerceptive Discovery, New Haven, CT, USA.
Eugenii A RabinerPerceptive Discovery, London, UK.
Sanjeev PathakAcadia Pharmaceuticals Inc., Princeton, NJ, USA.

Funding

Acadia Pharmaceuticals Inc.
6 · The paper itself

Abstract

Remlifanserin (ACP-204) is a selective 5-HT

Indexed as

KetanserinPiperazinesPiperidinesPositron-Emission TomographyReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor AgonistsAdultDose-Response Relationship, DrugFluorine RadioisotopesHalf-LifeHealthy VolunteersHumansMaleMiddle AgedUreaYoung AdultaltanserinFluorine RadioisotopesHTR2A protein, humanKetanserinpimavanserinPiperazinesPiperidinesReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor AgonistsUrea[18F]altanserin5‐HT2AACP‐204positron emission tomographyremlifanserin

Identifiers

PMID42677352
PMCPMC13531395

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.